Latest Oasmia Pharmaceutical AB Stories
UPPSALA, Sweden, April 20, 2015 /PRNewswire/ -- Oasmia Pharmaceutical AB ("Oasmia") announced today that its lead cancer product Paclical received market authorization
UPPSALA, Sweden, July 15, 2010 /PRNewswire-FirstCall/ -- - A Number of Promising New Product Candidates for Cancer Treatment, Within Both Human and Veterinary Oncology ABOUT OASMIA Oasmia is developing a new generation of drugs with emphasis on human and veterinary oncology.
ABBOTT PARK, Ill. and UPPSALA, Sweden, July 10 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Oasmia Pharmaceutical have announced a multi-year agreement to market one of the first cancer medications for dogs.
UPPSALA, Sweden, April 14 /PRNewswire-FirstCall/ -- Oasmia Pharmaceutical, Uppsala, Sweden, has been granted Orphan Drug designation by the USA FDA of Paclical(R) for the treatment of ovarian cancer.
- A young chicken: also used as a pet name for children.